1. Short title This Act may be cited as the Enhanced Clinical Trial Design Act of 2017 . 2. Patient access to experimental treatments (a) Public meeting (1) In general The Secretary of Health and Human Services (referred to in this Act as the Secretary ), acting through the Commissioner of Food and Drugs, in coordination with the Director of the National Institutes of Health, and in consultation with patients, health care providers, drug sponsors, bioethicists, and other stakeholders, shall, not later than 180 days after the date of enactment of this Act, convene a public meeting to discuss clinical trial inclusion and exclusion criteria to inform the guidance under subsection (c). The Secretary shall inform the Comptroller General of the United States of the date when the public meeting will take place. (2) Topics The Secretary shall provide a publicly available report on the topics discussed at the meeting described in paragraph (1) within 30 days of such meeting. Such topics shall include discussion of— (A) the rationale for, and potential barriers for patients created by, clinical trial inclusion and exclusion criteria; (B) how patient populations most likely to be affected by a drug can benefit from the results of trials that employ alternative designs, as well as potential risks associated with alternative clinical trial designs; (C) barriers to participation in clinical trials, including— (i) information regarding any potential risks and benefits of participation; (ii) regulatory, geographical, and socioeconomic barriers; and (iii) the impact of exclusion criteria on the enrollment in clinical trials of infants and children, pregnant and lactating women, seniors, individuals with advanced disease, and individuals with co-morbid conditions; (D) clinical trial designs and methods that increase enrollment of more diverse patient populations while facilitating the collection of data to support substantial evidence of safety and effectiveness